M84.550S Pathological fracture in neoplastic disease, pelvis, sequela

Name of the Condition

• Pathological Fracture in Neoplastic Disease, Pelvis, Sequela (ICD-10-CM: M84.550S)

Summary

This condition describes a pathological fracture in the pelvis resulting from underlying neoplastic disease, occurring during the sequela phase. The fracture is a complication of malignancy that has weakened the pelvic bone, leading to a fracture that persists beyond the active healing period. It represents the residual effects of the fracture and related bone changes following the acute phase of injury.

Causes

Pathological fractures in neoplastic disease arise when cancerous growths infiltrate or destroy pelvic bone tissue, compromising its structural strength. Primary bone cancers or metastatic tumors can erode the pelvis, leading to spontaneous or minimal-force fractures. Tumor-induced bone destruction or treatment-related effects (e.g., radiation therapy) may also contribute to the weakened bone, resulting in a fracture that progresses to the sequela stage.

Risk Factors

• History of cancer with bone metastasis to the pelvis.
• Advanced malignancies with skeletal involvement.
• Tumors that preferentially affect bone (e.g., multiple myeloma).
• Prior radiation therapy to pelvic sites.
• Systemic therapies that weaken bone.

Symptoms

• Chronic pain at the fracture site.
• Limited mobility or functional impairment.
• Visible deformity or instability in the pelvic region.
• Persistent swelling or tenderness.
• Difficulty with weight-bearing or ambulation.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies, and correlation with the patient's cancer history. X-rays or CT scans may show evidence of the healed fracture and residual bone changes. Bone scans or MRI can assess for ongoing tumor activity or metastasis. Laboratory tests may include tumor markers or bone turnover markers to evaluate disease status. The sequela phase is confirmed by the absence of acute healing signs and the presence of long-term effects.

Treatment Options

Treatment focuses on managing symptoms, supporting function, and addressing underlying malignancy. Pain management may include medications or physical therapy. Orthopedic interventions, such as bracing or surgical stabilization, can improve stability. Oncologic treatment (e.g., chemotherapy, radiation) targets the neoplastic disease to prevent further bone damage. Rehabilitation helps restore mobility and strength.

Prognosis and Follow-Up

Prognosis depends on the extent of the fracture, underlying cancer type, and response to treatment. Regular follow-up is essential to monitor for complications, such as nonunion or recurrent fractures. Imaging and clinical assessments guide ongoing care. Long-term management may involve periodic evaluations to address functional limitations or disease progression.

Complications

• Chronic pain or disability.
• Nonunion or malunion of the fracture.
• Recurrent fractures due to ongoing bone weakness.
• Infection or hardware failure (if surgery was performed).
• Progression of the underlying neoplastic disease.

Lifestyle & Prevention

• Maintain bone health through adequate nutrition (e.g., calcium, vitamin D).
• Engage in low-impact exercise to support mobility and strength.
• Avoid high-risk activities that may exacerbate instability.
• Follow oncologic treatment plans to control the underlying disease.
• Use assistive devices (e.g., walkers, canes) to reduce fall risk.

When to Seek Professional Help

Seek immediate care for severe pain, sudden mobility loss, or signs of infection (e.g., fever, redness). Contact a healthcare provider for worsening symptoms, new fractures, or concerns about cancer progression. Regular follow-up with both orthopedic and oncologic specialists is recommended for ongoing management.

Tips for Medical Coders

This code (M84.550S) is used for a pathological fracture in neoplastic disease of the pelvis during the sequela phase, indicating the fracture is in the residual stage after active healing. Documentation should specify the fracture's chronic nature, residual effects, and correlation with the neoplastic disease. Ensure the encounter aligns with the sequela phase and that the pelvic location and neoplastic cause are clearly documented.